Orion Oyj (ORNBVH.XC)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Liisa Hurme Ph.D. | President, CEO & Chairman of Executive Management Board | 1.25M | -- | 1967 |
| Mr. Rene Lindell M.Sc., Ph.D. | CFO & Member of Group Executive Management Board | -- | -- | 1976 |
| Mr. Olli Huotari Ll.M. | Senior VP of Corporate Functions, General Counsel, Secretary & Member of Executive Management Board | -- | -- | 1966 |
| Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.) | Senior VP of Generics and Consumer Health Business Division & Member of the Exe. Mgmt. Board | -- | -- | 1966 |
| Prof. Outi Vaarala M.D., Ph.D. | Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. Board | -- | -- | 1962 |
| Mr. Juhani Kankaanpaa | Senior VP of Global Operations & Member of Executive Management Board | -- | -- | 1980 |
| Mr. Niclas Lindstedt EMBA, M.Sc. | Senior VP of Animal Health Business Division & Member of the Exe. Mgmt. Board | -- | -- | 1966 |
| Mr. Hao Pan M.Sc. | Senior VP of the Branded Products Business Division & Member of the Exe. Mgmt. Board | -- | -- | 1971 |
| Ms. Julia Irene Macharey | Senior VP of People & Culture and Member of Management Board | -- | -- | 1977 |
| Mr. Tuukka Hirvonen M.Sc.(Soc.) | Investor Relations & Financial Communications Officer | -- | -- | -- |
Orion Oyj
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 3,943
Description
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid arthritis and cancer; and Dexdor, Precedex, and Dexmedetomidine products for human use. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other companies. It has discovery service and commercial license agreement with Invenra to develop bispecific antibody cancer therapeutics; and collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.
Corporate Governance
Upcoming Events
July 18, 2025 at 9:00 AM UTC
Orion Oyj Earnings Date
October 15, 2025 at 12:00 AM UTC
Ex-Dividend Date
Recent Events
Recent Events Information Not Available